New drug combo shows promise for rare eye cancer

NCT ID NCT01979523

Ongoing Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This study tested two drug combinations in 42 people with advanced uveal melanoma, a rare eye cancer that has spread. The goal was to see if adding a second drug (GSK2141795) to trametinib could better slow cancer growth. Participants were randomly assigned to receive either trametinib alone or both drugs together. The study measured how long it took for the cancer to progress and monitored side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC UVEAL MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic melanoma uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT UVEAL MELANOMA STAGE IV UVEAL MELANOMA AJCC V7

Contacts and locations

Locations

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Institut Curie Paris

Paris, 75005, France
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center

New York, New York, 10032, United States
The University of Liverpool

Liverpool, L69 3GA, United Kingdom
UT MD Anderson Cancer Center

Houston, Texas, 77030, United States
Vanderbilt University/Ingram Cancer Center

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.